Expertise in
11
conditions

Dr. Roland B. Walter

Hematology
Rachel Loschiavo PA-C
825 Eastlake Ave E, 
Seattle, WA 
Accepting New Patients
Offers Telehealth
26 Years of Experience
Expertise in
11
conditions
Rachel Loschiavo PA-C
825 Eastlake Ave E, 
Seattle, WA 

Overview

Roland Walter is a Hematologist practicing medicine in Seattle, Washington. He has been practicing medicine for over 26 years.

Dr. Walter is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Childhood Acute Myeloid Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 299 peer reviewed articles and participating in 14 clinical trials. Dr. Walter is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in WA

Hospital Affiliations

University Of Washington Medical Ctr

Languages Spoken

English
Arabic
Filipino
French
German
Hindi
Mandarin
Punjabi
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

PacificSource
  • PPO
Premera
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

Rachel Loschiavo Pa-C
825 Eastlake Ave E, Seattle, WA 98109
Other Locations
Gme Office University of Washington
1959 NE Pacific St, Seattle, WA 98195

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Phase 1/2, Multi-center, Open-label Study of IMGN632 Monotherapy Administered Intravenously in Patients With CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies
A Phase 1/2, Multi-center, Open-label Study of IMGN632 Monotherapy Administered Intravenously in Patients With CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2026
Intervention Type: Drug
Study Drug: IMGN-632 CD123-Targeting Antibody-Drug Conjugate
Study Phase: Phase 1/Phase 2
Randomized Phase 2 Trial of CPX-351 (Vyxeos) vs. CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less-Fit Adults With Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm
Randomized Phase 2 Trial of CPX-351 (Vyxeos) vs. CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less-Fit Adults With Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm
Enrollment Status: Completed
Publish Date: June 29, 2026
Intervention Type: Other, Biological, Drug
Study Drugs: Liposomal Daunorubicin, Liposomal Cytarabine, Cladribine, Cytarabine, Granulocyte Colony-Stimulating Factor, Mitoxantrone
Study Phase: Phase 2
A Phase I Study to Evaluate the Safety and Tolerability of Gemtuzumab Ozogamicin and Midostaurin When Used in Combination With Standard Cytarabine and Daunorubicin Induction for Newly Diagnosed FLT3-mutated Acute Myeloid Leukemia
A Phase I Study to Evaluate the Safety and Tolerability of Gemtuzumab Ozogamicin and Midostaurin When Used in Combination With Standard Cytarabine and Daunorubicin Induction for Newly Diagnosed FLT3-mutated Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: May 15, 2026
Intervention Type: Procedure, Drug
Study Drugs: Cytarabine, Daunorubicin Hydrochloride, Gemtuzumab Ozogamicin, Midostaurin
Study Phase: Phase 1
A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: August 14, 2025
Intervention Type: Drug
Study Drugs: Azacitidine, IMGN632, Venetoclax
Study Phase: Phase 1/Phase 2
A Long-term Follow-up Study of Patients Who Received VOR33
A Long-term Follow-up Study of Patients Who Received VOR33
Enrollment Status: Terminated
Publish Date: July 29, 2025
Intervention Type: Genetic
A First-In-Human, Open-Label, Multicenter Study of VOR33 in Patients With Acute Myeloid Leukemia Who Are at High-Risk for Leukemia Relapse Following Hematopoietic Cell Transplantation
A First-In-Human, Open-Label, Multicenter Study of VOR33 in Patients With Acute Myeloid Leukemia Who Are at High-Risk for Leukemia Relapse Following Hematopoietic Cell Transplantation
Enrollment Status: Terminated
Publish Date: July 29, 2025
Intervention Type: Biological, Drug
Study Drugs: VOR33, Mylotarg
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study of SL-401 as Consolidation Therapy for Adult Patients With Adverse Risk Acute Myeloid Leukemia in First CR, and/or Evidence of Minimal Residual Disease (MRD) in First CR
A Phase 1/2 Study of SL-401 as Consolidation Therapy for Adult Patients With Adverse Risk Acute Myeloid Leukemia in First CR, and/or Evidence of Minimal Residual Disease (MRD) in First CR
Enrollment Status: Terminated
Publish Date: October 17, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Single-Center Phase 1/2 Study of Single- or Fractioned-Dose Gemtuzumab Ozogamicin in Combination With G-CSF, Cladribine, Cytarabine, and Mitoxantrone for Previously Untreated Adult Acute Myeloid Leukemia or High-Grade Myeloid Neoplasm
A Single-Center Phase 1/2 Study of Single- or Fractioned-Dose Gemtuzumab Ozogamicin in Combination With G-CSF, Cladribine, Cytarabine, and Mitoxantrone for Previously Untreated Adult Acute Myeloid Leukemia or High-Grade Myeloid Neoplasm
Enrollment Status: Completed
Publish Date: August 30, 2023
Intervention Type: Biological, Drug, Other
Study Drugs: Cladribine, Cytarabine, Gemtuzumab, Granulocyte Colony-Stimulating Factor, Mitoxantrone
Study Phase: Phase 1/Phase 2
A Phase 1, Open-label, Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Activity of ADCT 301 in Patients With Relapsed or Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia
A Phase 1, Open-label, Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Activity of ADCT 301 in Patients With Relapsed or Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia
Enrollment Status: Terminated
Publish Date: February 26, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/2 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)
A Phase 1/2 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)
Enrollment Status: Completed
Publish Date: January 10, 2020
Intervention Type: Biological, Drug, Other
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

299 Total Publications

Pre- and post-transplant serum albumin levels and outcomes after allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia.
Pre- and post-transplant serum albumin levels and outcomes after allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia.
Journal: Leukemia & lymphoma
Published: July 06, 2026
Similar Doctors
Expertise in
21
conditions
Expertise in
21
conditions
Referral may be required

Rachel Loschiavo PA-C

825 Eastlake Ave E, 
Seattle, WA 
 (0.1 miles away)
206-288-1000
Languages Spoken:
English, Farsi, Hebrew, Russian, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Mazyar Shadman is a Hematologist practicing medicine in Seattle, Washington. Dr. Shadman is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), Non-Hodgkin Lymphoma, and Bone Marrow Transplant. Dr. Shadman is currently accepting new patients.

Expertise in
21
conditions
Expertise in
21
conditions
Referral may be required

Rachel Loschiavo PA-C

825 Eastlake Ave E, 
Seattle, WA 
 (0.1 miles away)
855-557-0555
Languages Spoken:
English, German, Portuguese, Russian, Ukrainian
See accepted insurances
Accepting New Patients
Offers Telehealth

Andrei Shustov is a Hematologist practicing medicine in Seattle, Washington. Dr. Shustov is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Anaplastic Large Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Shustov is currently accepting new patients.

Expertise in
18
conditions
Dr. Chaitra Ujjani
Hematology | Oncology
Expertise in
18
conditions
Dr. Chaitra Ujjani
Hematology | Oncology
Referral may be required

Rachel Loschiavo PA-C

825 Eastlake Ave E, 
Seattle, WA 
 (0.1 miles away)
206-606-1955
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Chaitra Ujjani is a Hematologist and an Oncologist practicing medicine in Seattle, Washington. Dr. Ujjani is highly rated in 18 conditions, according to our data. Her clinical expertise encompasses Chronic B-Cell Leukemia (CBCL), Follicular Lymphoma, Chronic Lymphocytic Leukemia (CLL), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Ujjani is currently accepting new patients.

Frequently Asked Questions about Dr. Roland B. Walter

How do I make an appointment with Dr. Roland B. Walter?

You can book an appointment with Dr. Roland B. Walter by calling their office at 206-288-7400. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Roland B. Walter a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Roland B. Walter is classified as an Elite expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Roland B. Walter specialize in?

While Dr. Roland B. Walter is a Hematology, they have specific expertise in Acute Myeloid Leukemia (AML), Leukemia, and Childhood Acute Myeloid Leukemia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Roland B. Walter participate in research or clinical trials?

Yes. Dr. Roland B. Walter has published 299 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Dr. Roland B. Walter's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Roland B. Walter accept my insurance?

Dr. Roland B. Walter accepts most major insurance plans, including PacificSource and Premera. We recommend calling the office directly at 206-288-7400 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Walter's expertise for a condition
ConditionClose
View All 25 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile